Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lequaglie, C.
Right arrow Articles by Ravasi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lequaglie, C.
Right arrow Articles by Ravasi, G.

Chest, Vol 100, 1053-1056, Copyright © 1991 by American College of Chest Physicians


ARTICLES

Prognosis of resected well-differentiated neuroendocrine carcinoma of the lung

C Lequaglie, C Patriarca, I Cataldo, G Muscolino, F Preda and G Ravasi
Department of Oncologic Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy.

Among lung tumors, well-differentiated neuroendocrine carcinomas are often misdiagnosed or may go unrecognized. Nineteen cases of well- differentiated neuroendocrine carcinoma (WDNC) were assessed at the National Cancer Institute of Milan over a ten-year period. There was only one woman and the age range was 50 to 77 years. Most of the patients were smokers (83 percent). All tumors were radically resected. There were 12 lobectomies, two sleeve-lobectomies, three bilobectomies, one pneumonectomy, and two segmentectomies (one patient had two synchronous WDNCs). There was neither operative mortality nor major complications. Sixteen tumors were stage 1, three were stage II, and one was stage IIIa. Five patients had adjuvant chemotherapy (cyclophosphamide, doxorubicin, and vincristine [CAV] regimen). One patient was given local or regional radiotherapy. In ten patients the tumors recurred, even though four had had adjuvant treatment. The brain was the first site of metastasis in seven cases. The pathologic stage seemed not to be closely related to the appearance of metastases (six patients with stage I disease had recurrences). Only two patients with recurrence were still alive 12 and 103 months after the procedure. The percentage of survival for patients with stage I disease after more than 100 months was 68 percent. WDNC is similar to small-cell lung carcinoma (SCLC) with regard to the neurotropism of metastases. Surgery is curative for more than one half of the patients with localized disease. Therefore, multimodal therapy, probably based on tumor behavior and investigations of tumor markers, is advisable.


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Garcia-Yuste, J. M. Matilla, A. Cueto, J. M. R. Paniagua, G. Ramos, M. A. Canizares, I. Muguruza, and Members of the Spanish Multi-centric Study of Neur
Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung
Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 192 - 197.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Zaffaroni, R. Villa, U. Pastorino, R. Cirincione, M. Incarbone, M. Alloisio, M. Curto, S. Pilotti, and M. G. Daidone
Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres
Clin. Cancer Res., April 15, 2005; 11(8): 2832 - 2839.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Garcia-Yuste, J. M. Matilla, T. Alvarez-Gago, J. L. Duque, F. Heras, L. J. Cerezal, and G. Ramos
Prognostic factors in neuroendocrine lung tumors: a Spanish multicenter study
Ann. Thorac. Surg., July 1, 2000; 70(1): 258 - 263.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
V. W. Rusch, D. S. Klimstra, and E. S. Venkatraman
Molecular Markers Help Characterize Neuroendocrine Lung Tumors
Ann. Thorac. Surg., September 1, 1996; 62(3): 798 - 809.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Chest Physicians.